Background: Juvenile onset SLE (JSLE) is a severe autoimmune condition with LN seen in up to 80% of patients [1] . Current methods of monitoring renal disease activity over time rely on a variety of standard laboratory markers and the use of disease activity tools such as the British Isles Lupus Assessment Group (BILAG) index score. Improving monitoring and predicting disease activity may allow earlier intervention and improve long-term renal outcome. Aims and Methods: This prospective longitudinal study aimed to identify whether standard and/or novel biomarkers are useful for monitoring and predicting LN disease activity. Using patients recruited to the UK JSLE study, urine and blood samples were collected during routine clinical reviews. The study had full ethical approval.
Results: The JSLE cohort (n ¼ 64), seen at three [interquartile range (IQR) 2-5] clinical reviews over 364 (182-532) days, were aged 14.1 (11.8-15.8) years and 80% female. Active renal episodes (23% total; renal BILAG A/B) had significantly increased concentration of monocyte chemoattractant protein 1 (MCP1), neutrophil gelatinase-associated lipocalin (NGAL), ESR, anti-dsDNA, urine albumin:creatinine ratio (UACR), creatinine and reduced complement 3 (C3), C4 and lymphocytes. Multivariate analysis demonstrated MCP1 and C3 as independent variables (P < 0.001) for active renal disease. MCP1 was an excellent predictor of improved renal disease [area under the curve (AUC) 0.81; P ¼ 0.013; concentration 343 pg/ml, specificity 71%, sensitivity 70%]; NGAL was a good predictor of worsened renal disease activity (AUC 0.76; P ¼ 0.04; concentration 30 ng/ml, specificity 60%, sensitivity 61%). Urine MCP1 and uNGAL changed as subsequent renal disease changed (MCP1 P ¼ 0.015; NGAL P ¼ 0.038). Standard markers could not predict disease activity.
Conclusion:
We have demonstrated that biomarkers (MCP1, C3) perform well for monitoring renal disease in JSLE, and novel biomarkers (MCP1, NGAL) outperform standard markers for predicting change. Biomarker-led monitoring may facilitate titration of medication and allow earlier diagnosis and intervention. Collaboration with industry to develop point of care urine biomarker testing is now in progress.
Disclosure statement: The authors have declared no conflict of interest.
Background: Despite recent advances in the management of children with JIA, complete clinical remission is uncommon. A state of minimal disease activity (MDA) is a useful therapeutic goal. Recently, a definition of MDA has been proposed [1] , with discrete definitions for oligoarticular [physician global assessment (PGA) 2.5 cm and swollen joint count (SJC) ¼ 0] and polyarticular [PGA 3.4 cm, parent global assessment 2.1 cm and SJC 1] disease patterns. The definition cannot be applied to enthesitis-related arthritis (ERA) but is applicable to all other ILAR subtypes.
Objective: To describe the proportion of children with JIA reaching MDA over time, during the first 2 years after diagnosis. Methods: All children in the Childhood Arthritis Prospective Study (CAPS) with available data were included. MDA was determined for all children (except ERA) at presentation, and at 6, 12 and 24 months after diagnosis and presented for the entire cohort and within the oligoarticular and polyarticular subsets. The proportion of children in MDA with oligoarticular and polyarticular pattern disease was compared at all time points, using 2 statistics. Results: To July 2012, 1236 children had been recruited to CAPS: median age at disease onset 6.7 years [interquartile range (IQR) 2.8-10.7], median disease duration 5.2 months (IQR 2.4-10.6), 64% female. Data to calculate MDA were available in 799, 673, 625 and 473 children at baseline and 6, 12 and 24 months, respectively. A minority of children were in MDA at presentation but this increased to 61% at 1 year and remained stable at 2 years (Table 1) . Significantly more children with oligoarticular pattern disease were in MDA at all time points. Conclusion: Although the aim of treatment in JIA is remission, only 65% of children with JIA had reached MDA after 2 years of follow-up, suggesting a significant level of ongoing disease activity. Understanding why a high proportion of children persist with higher levels of disease activity, despite advances in therapies, may help to improve targeting of therapies in the future. Disclosure statement: The authors have declared no conflict of interest. 
O5. AUDIT OF INCIDENCE OF SCARRING FOLLOWING STEROID TENDON INJECTIONS FOR TENOSYNOVITIS IN CHILDREN WITH JIA: A SINGLE-CENTRE EXPERIENCE
Akhila Kavirayani, M. S. Thyagarajan, Jane Ellis, C. N. S. Helen Strike and A. V. Ramanan Bristol Royal Hospital for Children, Bristol, UK Correspondence to: akhilamk@yahoo.com
Background: Superficial skin scarring is a well-recognized complication of steroid joint injections in JIA with an approximate incidence of 2%. With increasing recognition of tenosynovitis, more steroid tendon injections are being performed. There are no published studies on the incidence of scarring secondary to steroid tendon injections in children.
Objective: The aim of this study was to evaluate the incidence of scarring following steroid tendon injections done by an interventional paediatric radiologist in children with JIA.
Methods: All children with JIA who underwent tendon injections in Bristol Children's Hospital were identified from the Paediatric Rheumatology database. A proforma was devised and relevant information collected from medical notes, including number of episodes of tendon injection and specific tendons injected. Scarring was identified either by documentation in notes or a telephone call to the parents, with explanation of anatomical landmarks.
Results: 17 patients with JIA had steroid tendon injections over a period of 2.5 years. The median age was 9 years (range 2.5-16). There were 24 episodes of tendon injection, with a total of 36 tendons injected, all around the ankle. Tenosynovitis was diagnosed by US in 83% of episodes and MRI scan in 17%. 58% had arthritis of the adjacent joint. The median interval between detection of tenosynovitis and injection of tendons was 7 weeks. All injections were done using triamcinolone hexacetonide and performed under general anaesthetic with US guidance by an interventional paediatric radiologist. Lidocaine was instilled in 7/24 (29%) episodes. Scarring of injection site was identified in 9/24 (37%) episodes and 6/17 (35%) patients. Deep scars occurred in three patients. Five patients had repeat tendon injections, of whom four had scarring (80%). There was no clear pattern of association of scarring with dose of steroid or administration of lidocaine.
Conclusion:
In our retrospective series of 17 JIA patients who had steroid tendon injections, scarring was observed in 35%. In patients in whom tendon injections were repeated, the incidence of scarring was 80%. Our data seem to suggest that steroid tendon injections for tenosynovitis in JIA patients might be associated with a higher incidence of scarring as compared with joint injections. This information might be useful when obtaining informed consent for the procedure. Prospective studies recruiting a larger cohort of patients are needed to substantiate these findings. Background: Currently there is limited evidence supporting podiatric treatment of children with JIA. This study aimed to investigate whether pre-formed cost-effective foot orthoses (FOs) impacted on pain, quality of life (primary outcomes) and/or gait parameters (secondary outcomes) in children affected by JIA. Methods: Intervention was blinded to the patients. The trial group was supplied with FOs, with the addition of chairside corrections and the control insole instead was made without corrections. Both insoles had the same black EVA top cover. Primary outcome measures were recorded at each of three data recording appointments over a 6-month period, using validated questionnaires such as VAS, Childhood Health Assessment Questionnaire (CHAQ) and PedsQL. Tekscan equipment (F-Scan and HR Walkway) measured in-shoe pressure and force data with and without orthotic intervention, using same type of sensors of equal resolution. Multiple foot strikes and repetitive gait patterns were compared pre and post-treatment. The HR Walkway captures multiple sequential footsteps during barefoot walking; allowing barefoot and inshoe measurements to be compared. Results: Sixty children were recruited: 48.3% (n ¼ 29) control and 51.7% (n ¼ 31) active-treatment group. Within the control group 20.7% (n ¼ 6) of patients were male. Within the active-treatment group, 29% (n ¼ 9) of subjects were male. Age range was 5-18 years, mean age for the control group was 11.17 (S.D. 3.51) and for the trial group was 10.64 (S.D. 3.84). In order to attribute any effect solely to the FO intervention, details of changes of medication and/or new joint injections were recorded during the trial: 65.5% (n ¼ 19) of the control group were on stable medication; 74.2% (n ¼ 23) of the children receiving active treatment were on stable medication. Overall, 99.4% (n ¼ 179/180) of appointments were completed and contributed to this preliminary data analysis. Significant improvement was identified in the primary outcomes favouring active treatment with regard to pain and quality of life measures: VAS (P < 0.05); CHAQ (P < 0.05); PedsQL paediatricgeneric (P < 0.05), Peds paediatric rheumatology (P < 0.05); PedsQL parent generic (P < 0.05); PedsQL parent rheumatology (P < 0.05). Significant differences were also identified between the groups for gait time, stance time, total plantar surface, heel contact, midfoot, fifth metatarsal head and distal phalanx.
Conclusions:
The results show that FOs are effective in improving pain, quality of life and most gait parameters in JIA children. This trial also provides new evidence for the role of podiatrists within the multidisciplinary team in paediatric rheumatology and hopes to improve the profile of podiatrists working within paediatric hospitals and private practices. Disclosure statement: The authors have declared no conflict of interest.
GET A GRIP
K. W. Brimlow and S. Rangaraj Nottingham Children's Hospital, Nottingham, UK Correspondence to: Kath.Brimlow@nuh.nhs.uk Background: The Childhood Myositis Assessment Score (CMAS) is a validated assessment tool for JDM. The CMAS 14 correlates highly with the Childhood Health Assessment Questionnaire (CHAQ) score and manual muscle testing. It correlates moderately with the physician-assessed global disease score [1] . It takes 20 min to complete and tests endurance and stamina. Grip strength is important as a measure of general health and is often used in screening for normal motor function. It is one of the most reliable clinical measurements for estimation of strength and is used extensively on adults [2] . We routinely test hand grip strength using the Clifton NJ Jamar hand hydraulic dynamometer on patients with JDM. Objective: To analyse hand grip strength in JDM patients and compare this with CMAS scores. Methodology: This was a retrospective audit. CMAS and Jamar grip strength scores were recorded from the medical notes for 12 patients. The Jamar is generally thought to be durable, cost effective and has good inter-observer and intra-observer reliability. It measures isometric grip force from 0 to 90 kg (0-200 lbs). It has five grip settings and we always use the second setting. We used the Guidelines in the American OT Journal 1986 for using the Jamar [3] . The best score of three was taken. The American OT Journal published average scores for normal children aged 6-19 (adults to 75 years). Results: Some trends were noted: normal grip strength scores were low compared with the scores for similar aged normal children. Due to the low numbers the results were not statistically significant to conclude whether hand grip strength in JDM patients correlates with CMAS score. Conclusion: There is evidence that grip strength is a predictor of total muscle strength in healthy children and adolescents [4] . However, there is also evidence that grip strength does not correlate with lower limb strength in patients with pathology [5] . Therefore we recommend that both CMAS and hand strength are tested for this group of patients. The evidence is not clear in this area and therefore further research is required. Disclosure statement: The authors have declared no conflict of interest.
Background: The Bath Ankylosing Spondylitis Metrology Index (BASMI) is an objective measure of axial involvement in AS and is validated for use in adults. There are no published data relating to its use in children. Objectives: This pilot study was conducted to assess whether BASMI is a usable tool in children and young people with enthesitis-related arthritis (ERA). Method: BASMI is a standardized assessment tool using five measurements (tragus-wall, lumbar flexion, intermalleolar distance, lumbar side flexion and cervical rotation). Over a 3-year period 14 children with a diagnosis of ERA were identified as suitable for assessment. Results: Of the 14 children assessed, 12 were HLA B27 þ and all had a diagnosis of ERA confirmed by a paediatric rheumatology consultant. There were 11 males and 3 females; the average age at time of initial assessment was 13.4 years; 11 of the individuals had only a single BASMI assessment completed; 3 had sequential measurements done over a 1-to 3-year time period. In the age range assessed (11-16 years), the BASMI was carried out as per the standardized adult format. It proved easy to use and took less than 5 min to complete with each child. Those individuals who had sequential measurements showed improvement in all areas during the assessment period. In one individual in whom Childhood Health Assessment Questionnaire (CHAQ) scores were available at the same time points, no correlation was noted. BASMI scores appeared more closely related to patient global score. Some measures appeared to be more responsive to change than others, e.g. tragus-wall showed little change over time and therefore may be a less useful measure in this age group. Conclusion: This small pilot study demonstrated that BASMI can be used in the paediatric age group and was well tolerated by children and teenagers. With the BASMI the score is added up and divided by 5 to give a score out of 10. In this population it was found to be more sensitive to change as a score out of 50 when charting sequential measurements. Sequential BASMI measurements appear to be a useful method of determining a trend of improvement or deterioration and might prove a useful additional tool for documenting response to treatment in this patient group. This adapted BASMI should be validated in a larger cohort of children with ERA and correlated with other markers of disease activity. Background: Childhood chronic non-infectious uveitis is a rare disease that is difficult to treat. In spite of current treatment regimens with two immunosuppressive agents, there is still a high rate of ocular complications in children with uveitis (40%). This can result in significant visual impairment. Objective: To assess the safety and efficacy of triple immunosuppressive therapy in the treatment of refractory chronic non-infectious childhood uveitis. Methods: A retrospective study was performed on all patients diagnosed with chronic, non-infectious uveitis under the age of 16 who had at some stage been treated with triple immunosuppressive therapy for at least 6 months at the combined paediatric rheumatology-ophthalmology clinic. Triple therapy was defined as using any three immunosuppressive agents simultaneously (MTX, MMF/tacrolimus and an anti-TNF agent is the most likely combination). The main outcome measures recorded were: anterior chamber cell grade, ability to reduce topical corticosteroids, presence of ophthalmic complications, serious adverse events and side effects. Results: Nine patients were included in the analysis; all had been unresponsive to previous treatment with two immunosuppressive agents.
Before triple therapy started, 14 of the 18 eyes had active anterior uveitis and were being treated with topical corticosteroid drops. Six months after commencement of triple therapy, there was a clinically significant improvement in ocular inflammation in seven of these eyes and nine were receiving a tapered dose of topical corticosteroids. Over the course of follow-up, ocular inflammation fluctuated and six of the nine patients required additional steroids for uveitis.
During the follow-up period, there were three serious adverse events recorded, which were: one episode of chicken pox and two episodes of pneumonia that required admission to hospital. Conclusion: In terms of efficacy, initial results show triple therapy did improve control of uveitis in certain patients. However, in terms of safety, results suggest triple therapy could potentially be associated with serious adverse events. Disclosure statement: The authors have declared no conflict of interest. Methods: Retrospective case-note review of patients needing uveitis screening was performed. Patients at QMC referred for ophthalmology screening over a 6-month period were identified, while patients at SCH receiving an initial diagnosis of JIA over a 2-year period were identified. Data were collected using a common proforma, analysed and compared. Results: In both centres oligoarthritis was the most common subtype of JIA with 29% at QMC (n ¼ 29) and 60% at SCH (n ¼ 25). QMC referred 100% of patients for an initial ophthalmology screening after JIA diagnosis compared with 84% at SCH. At QMC 83% of those patients had their screening appointment within the 6-week guidelines compared with 71% at SCH. 59% of patients at QMC continued to have follow-up screening after the initial ophthalmology appointment compared with 86% at SCH. Conclusion: Neither centre adhered closely enough to screening guidelines. Interesting differences between the two centres included: (i) QMC patients were more likely to receive their initial screening appointment within 6 weeks of referral; and (ii) SCH patients were more likely to receive follow-up screening adhering to guidelines. Audit findings have been presented and discussed at established regional network meetings co-organized by QMC and SCH. Shared best practice has been reflected in changes instituted at each centre informed by practice strengths and weaknesses identified through this audit. A regular programme of regional audit is now planned and collaboration with other centres would be welcome. Disclosure statement: The authors have declared no conflict of interest. Background: There is increasing interest in the role that tele and video conferencing can play in access to postgraduate medical education, particularly for small specialties that are spread over large geographical areas. During the BSPAR Trainees' Meeting in January 2012, there was request and enthusiasm for the development of further postgraduate educational resources. It was proposed that a trainees' educational teleconference meeting be piloted for 6 months with the aim of aiding postgraduate training. Methods: Monthly invitations were sent to all trainees on the BSPAR trainee mailing list (total n ¼ 55, Paediatric Rheumatology Grid trainees n ¼ 12), asking them to email the Chair if they wished to participate. Trainees were invited to present a case with literature review. PowerPoint presentations were emailed to the Chair then circulated only to those attending the meeting. Presentations did not include any patient-or hospital-identifiable information and consent had been obtained. The teleconference was financed by a combination of residual funds from the BSPAR Trainees' Meeting and self-funding of the cost of a local telephone call. Results: Six trainee teleconferences have been held, on the third Tuesday of each month between 8 and 9 pm, chaired by the Royal College of Paediatric and Child Health Specialist Advisory Committee (CSAC) for Higher Specialist Training in Paediatric Rheumatology trainee representative. The format of the meeting consisted of an initial discussion of CSAC/Clinical Studies Group (CSG)/BSPAR trainee issues followed by the educational session. The mean number of trainees attending each meeting has been 7.8 (range 5-13) from 6.2 (4-10) centres. Topics have included eosinophilic fasciitis, consensus treatment for JDM, debate of anakinra as first-line treatment in systemic onset JIA, SLE and antiphospholipid syndrome, and SLE and transverse myelitis. Discussion feedback has been positive. Use of PowerPoint presentations has worked well via phone and generated lots of discussion. The majority of Grid trainees attended. Technical difficulties have occurred on two occasions but were quickly resolved. The meetings have provided closer links between CSAC, CSG and BSPAR trainee representatives and support for trainees across the country. Skills in teleconferencing have been gained. It is acknowledged that this method of education does not replace the advantages of face-to-face educational events. However, it can be a useful additional resource for sharing and learning from experience. Submitted on behalf of BSPAR trainees. Disclosure statement: The authors have declared no conflict of interest. Background: Addressing and delivering educational needs for health care professionals working in a clinical network is challenging, particularly for small specialties that are spread over large geographical areas. This is pertinent in Paediatric Rheumatology. There is increasing interest in the role that videoconferencing can play as a mechanism of increasing access to medical education within a clinical network. The Scottish Paediatric and Adolescent Rheumatology Network (SPARN) was established formally in 2009. A learning needs analysis identified an unmet need for medical education. It was proposed that a videoconference education programme be established with an aim of addressing these unmet educational needs. Methods: The educational videoconference session was initially trialled between the two tertiary centres. Technical issues were resolved, then other network centres were invited to attend (n ¼ 14). Topics included a range of paediatric rheumatology topics suggested by the learning needs analysis. Interdisciplinary presenters were coordinated from the two tertiary centres. The educational programme was advertised on the SPARN website and e-mail list (n ¼ 122). Local centres were responsible for coordinating their hospital videoconference facility. A multisite bridge linked participating centres. Central technical support was provided by the Telemedicine Department at Yorkhill Hospital, Glasgow. When case presentations were used no identifiable information was presented and consent had been obtained. Results: 18 videoconference teaching sessions, each lasting 2 h, have now been held, on a monthly basis since October 2010. The number of centres attending has increased (n ¼ 14) and included representatives of multidisciplinary professions of the network. Topics have included generic teaching on JIA, paediatric CTDs, JDM, infection and rheumatology, non-organic pain syndromes, orthopaedic problems in rheumatology and medications used in paediatric rheumatology. A joint session on vasculitis was hosted between SPARN and Scottish Paediatric Renal Network (SPRUN) in 2012. Discussion: Feedback has been positive. Use of videoconferencing has generally worked well and technical issues have improved since its initiation. The educational sessions have provided closer links between network centres. Although geographical barriers have been overcome, finding a suitable and convenient time remains difficult. Pitching education at suitable levels for all members of the multidisciplinary team remains challenging. It is acknowledged that this method of education does not replace the advantages of face-to-face educational events but can be a useful additional resource for supporting education within a clinical network. Disclosure statement: The authors have declared no conflict of interest.
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THE ROLE OF TELECONFERENCING AS AN EDUCATIONAL RESOURCE FOR PAEDIATRIC RHEUMATOLOGY TRAINEES
Mary
THE ROLE OF VIDEOCONFERENCING AS A METHOD OF EDUCATION DELIVERY WITHIN A PAEDIATRIC RHEUMATOLOGY CLINICAL NETWORK
THE ROD AMOS RHEUMATOLOGY EDUCATION (RARE) DAY: PART OF THE SOLUTION TO CLINICAL SKILLS TRAINING IN PAEDIATRIC AND ADOLESCENT RHEUMATOLOGY?
Rachel Background: In paediatric and adolescent rheumatology (PAR), professionals lack confidence in joint examination [1] , routine documentation of pGALS examination is poor [2] and yet clinical skills training in busy hospital environments is challenging. Experience with patients-as-educators [3] , in the context of evidence regarding simulation-based skills training, has led to an adult rheumatology virtual ward round (VWR) being established for Sheffield medical students. This has been positively evaluated [4] but this teaching method is not previously reported in PAR. Local concern was expressed that children and young people's (CYP) participation in such an innovation would be problematic. We present a multiprofessional PAR education day comprising a VWR of patients from our service, problem-based learning sessions and lectures. Objectives: To improve VWR participant's clinical joint examination skills and pilot the extension of VWR methods to encompass CYP as patient-educators. Methods: Forty health care professionals from paediatric and adult backgrounds (doctors, nurses, therapists, medical students) attended. The course was free with refreshments funded by Pfizer and participant/educator expenses from a charitable donation. We recruited by personal invitation 16 CYP (4-25 years) and 2 adults (30, 41 years) for the VWR. The morning session was the VWR preceded by a quiz to establish baseline knowledge. Participants in groups of five rotated through eight stations (20 min) with two/three patients and one educator. Educators were paediatric rheumatologists from the Yorkshire Paediatric Rheumatology Network Group (YPRNG) and Sheffield nurse specialists/therapists. The afternoon session comprised lectures and problem-based learning, facilitated by national experts. Finally, the quiz was repeated to assess learning. Quiz results and feedback from patients, participants and educators were collected. Results: 80% of VWR participants reported only some confidence in examining joints pre-course whereas 70% felt confident in most aspects of pGALS afterwards. Similar improvements were demonstrated in knowledge of JIA with positive participant feedback. Consistent themes from patients/families' feedback included being 'keen to give something back' and 'wanting to help others' by participating in the VWR. Even the youngest tolerated it well and concerns regarding missing school/work were overridden as being 'just like another appointment'. Conclusions: The VWR is applicable to CYP and was positively evaluated by clinicians, participants and patients. Joint PAR training and simulated clinical scenarios are effective and focus efforts in times of scarce resources. Patients As Rheumatology Teachers are a beneficial PART of improving training. We recommend the RARE day as a practical and applicable model for innovating education in PAR. Disclosure statement: The authors have declared no conflict of interest. [1] . The standards are aimed at achieving optimal care but recent audits [2, 3] have shown that UK paediatric rheumatology falls short of the standards, even in tertiary centres. Ideally all standards should be met, but implementation will take time and resources. It is critical that the views of young people and their families are sought when prioritizing standard implementation.
A STUDY OF HOW PATIENTS AND PARENTS RATE THE
Objective: As part of the development of a regional paediatric rheumatology network in the east of England we sought the views of children and families on the standards of care and on their willingness to travel for tertiary centre care. Method: A questionnaire was sent out to patients and parents from six centres across the region from 15 May 2012 to 15 August 2012. These included a small district general hospital (DGH), four medium sized DGHs and one teaching hospital offering tertiary level paediatric rheumatology. The questionnaire was adapted from one used previously in the Oxford region [4] . It asked patients/parents to rate each standard as either vital, very important, important or useful. They were then asked to go back and rank their top 10 standards. A secondary section asked their views on frequency of attendance and acceptable travel time to a regional tertiary centre. Results: 33 questionnaires were returned in the time frame of the study. Five did not rank a top 10 and three miss-ranked their response. Standard 4 was ranked as number 1 by 8/33 responders. 23 of the 43 standards were ranked vital more than other category. 40% of responders felt they shouldn't travel for longer than 1 h and 37.5% felt they should be seen at least three times per year in a tertiary centre. Conclusion: Children and parents feel that the majority of standards are vital and should be part of the standard care they receive. They ranked the use and regulation of drugs most highly, but skill in recognizing the diagnosis, as well as early referral to specialist care, was also prioritized. A minimum of annual review in a tertiary setting was vital, however, the majority want to be seen more often, with this specialist care close at hand. Disclosure statement: The authors have declared no conflict of interest. Background: In the Yorkshire and Humberside Paediatric Rheumatology Network every child with JIA requiring non-tariff medications that are not NICE approved, requires an individual funding application to the relevant Primary Care Trust. With commissioners for our network we are trying to develop agreed guidelines to simplify this process. Towards this a description of the current practice of all UK centres would be helpful. Objective: We aimed to collect and describe this information for this process and to share with all UK centres. We have focused on the situations where the use of non-tariff treatments are sought therefore have concentrated on JIA that is resistant to the first-line treatments that we use within our network. Methods: An online survey was designed, posing questions around specific scenarios for patients with different subtypes of JIA and uveitis. Participants were invited to rank treatment options in the order that they would use them, following failure of described therapies. All consultants on the BSPAR mailing list were invited to take part. A follow-up targeted email will be sent to consultants in the centres not represented with additional data anticipated. Results: 13 consultants covering 10 regions completed the survey.
Some results of note are:
(i) In RF-positive polyarthritis, RF-negative polyarthritis and PsA the first choice of drug following failure of the first anti-TNFa agent was a second anti-TNF in 80% of respondents and for 92%, 100% and 100% of respondents respectively within the first three choices. (ii) In RF-positive patients rituximab (8/13 respondents) and abatacept (8/13 respondents) were in the top three choices. (iii) In RF-negative patients choices were more variable between abatacept (7/13), tocilizumab (6/13) and DMARDs (5/13) for the top three choices. (iv) In systemic JIA, patients with arthritis-predominant ongoing disease process were more likely to be prescribed anti-TNFa or tocilizumab following MTX failure, whereas there was a 2:1 split between tocilizumab and anakinra for those with ongoing systemic symptoms. (v) In JIA-associated uveitis adalimumab was most often prescribed after MTX, whereas in idiopathic uveitis MMF or adalimumab was used with almost equal frequency.
More detailed results can be provided. Conclusion: We hope that this description of current UK practice will help inform discussions with commissioners and possibly act as a starting point for future UK guidelines. Disclosure statement: The authors have declared no conflict of interest. Background and objectives: Understanding the short-and long-term safety of etanercept (ETN) use in children with JIA is of paramount importance to patients, families and the rheumatology community. However, when interpreting adverse events, it is important to consider the burden of co-morbidity among children starting new therapies for JIA, which may increase the risk of certain adverse events. Therefore, the aim of this analysis was to describe and quantify the baseline medical and health conditions among children newly starting either ETN or MTX for JIA.
BASELINE CO-MORBIDITIES IN PATIENTS WITH JIA STARTING ETANERCEPT OR METHOTREXATE: RESULTS FROM THE BSPAR ETANERCEPT REGISTER
Methods: The national BSPAR ETN register was established in 2004 to monitor the safety and effectiveness of ETN in children with JIA. A comparison cohort of children with JIA who are biologic naive starting MTX was also recruited. To 31 December 2011, 876 patients with JIA were enrolled (ETN 679, MTX 197). Rheumatology centres were asked to provide a list of all co-existing medical conditions and whether they were active at the time of drug start. These co-morbidities were medDRA coded and grouped into one of 16 categories. Comparisons between the cohorts were made using non-parametric descriptive statistics. Results: ETN patients were older with a mean age of 11 years compared with 8 years in the MTX cohort. They also had longer median disease duration (ETN 4 years, MTX 1 year). Within both cohorts, 44% patients had at least one co-morbidity (ETN 46%, MTX 37%), with a higher proportion of children starting ETN having multiple co-morbidities (ETN 22%, MTX 11%). The most frequent comorbidities presented were atopic conditions, chronic anterior uveitis and congenital/genetic/developmental conditions. There were some differences in co-morbidities between the groups, for example ETNtreated patients were more likely to have osteopenia or osteoporosis (ETN 6%, MTX 0%) and growth/developmental abnormalities (ETN 9%, MTX 3%), which may be explained by the longer disease duration in this cohort. ETN patients also presented with more eye (ETN 6%, MTX 1%) and renal conditions (ETN 6%, MTX 2%). Conclusion: Co-morbidity is common among children with severe JIA, with a similar distribution between treatment groups. ETN-treated patients had more co-morbidities overall and so should be considered when interpreting long-term outcomes amongst these patients. Background: The introduction of biologic therapies has revolutionized the management of JIA. Previously, the only choice of licensed therapy in the UK was etanercept (ETN), with adalimumab (age 4 years), abatacept (age 6 years) and tocilizumab (systemic arthritis) more recently included. Objective: The objective of this analysis was to describe non-ETN biologic pattern of use in children with JIA. Methods: The Biologics for Children with Rheumatic Diseases (BCRD) study is an ongoing prospective observational cohort study that has been collecting detailed information on children <18 years of age starting a non-ETN biologic therapy for JIA since 2010. Detailed demographic and disease information, including past biologic therapies, are collected at baseline. Using non-parametric descriptive statistics the use of non-ETN therapy as a first-line or subsequent biologic therapy was compared, including patterns of prescription, use under licensed indications, ILAR subtypes and disease activity/ severity. Results: To 08/16/2012, 148 children across the UK were recruited: median age 10 years, 64% female. The most common ILAR subtypes were systemic arthritis (30%) and RF-negative polyarthritis (26%). Seventy-one patients (48%) were starting a non-ETN biologic as firstline biologic therapy, of which 35 (49%) were prescribed off-licence, largely accounted for by infliximab and anakinra. First-line biologic users were a younger cohort compared with subsequent biologic users (P ¼ 0.0077). All patients on anakinra had systemic arthritis, whereas only 73% of tocilizumab patients used it for this licensed indication. Forty-five per cent of first-line users vs 25% of subsequent users had a history of chronic anterior uveitis (P ¼ 0.031). Of those registered at the point of starting a second-line biologic, 78% had received prior ETN. The majority of all patients receiving previous biologic treatment had received only one prior biologic (71%) although 18 children had received two prior biologics, 3 children had received three and 1 child (RF negative) had received five previous biologics. Subsequent biologic users had a higher limited joint count (P ¼ 0.0026). Conclusions: In the UK, many children are now receiving non-ETN biologics, although almost half of these are being prescribed offlicence. Continual follow-up in children with JIA will help to address questions of the best choice of biologic therapy, as both first-line and subsequent treatment, as well as determine the safety of these drugs in children, for which limited clinical experience exists. Disclosure statement: The authors have declared no conflict of interest. A total of 44 hips were injected during this period. 31 hips were injected for the first time, 9 hips were injected for a second time and 4 hips needed a third episode of injection. Efficacy was assessed on a followup visit at least 3 months after the joint injection. Duration of effect was calculated up to the last follow-up visit. Efficacy was 71% for the first episode and 89% for the second episode. Duration of response was for a mean period of 7 months (range 1-30 months). Imaging on followup was done if there was clinical suspicion of disease activity. Of 31 hips injected, on follow-up, activity was suspected in 18 hips (58%), of which normal imaging was found in 10 hips (55%), evidence of ongoing disease activity in the form of joint effusion/synovial thickening was found in 9 (50%) and disease-related damage in 1 (5%). Of the 9 hips injected for a second time, the effect lasted for a mean period of 8.9 months (range 4-15 months). There was one episode of cutaneous bruising (2.3%) and no evidence of avascular necrosis was found in any hip on imaging at the last follow-up. Conclusion: US-guided hip injections carried out by a paediatric rheumatologist are safe and efficacious. They could be a potential alternative to fluoroscopically guided joint injections, avoiding radiation in children. Disclosure statement: The authors have declared no conflict of interest. Background: Delays in access to specialist care for children with paediatric rheumatic disease are likely to be associated with adverse outcomes [1, 2] . Factors influencing access to care for juvenile onset SLE (JSLE) remain mainly unknown. Objectives: We aimed to investigate factors that may influence the interval between symptom onset and JSLE diagnosis within a UK cohort. Methods: Data from 257 patients recruited to the UK JSLE Cohort Study [3] were analysed. Potential predictors of access to care explored included: socioeconomic status, ethnicity, gender, age at presentation, presenting features, ACR criteria, origin of referral to paediatric rheumatology, distance from nearest tertiary paediatric rheumatology service and family history of autoimmune disease. Correlation tests were employed to identify variables associated with a log of time between symptom onset and diagnosis (P < 0.1). Linear regression was then used to identify independent predictors of access to care. Results: 257 children from across the UK with JSLE were included in the analysis (216 female, 41 male, ratio 5.3:1). Median time from symptom onset to diagnosis was 0.37 years [range 0-14.07 years, interquartile range (IQR) 0.17-1.38]. Median distance to a tertiary paediatric rheumatology centre was 20.5 miles (IQR 9.2-41.5). The JSLE cohort population Index of Multiple Deprivation scores were found to be higher than for the English population as a whole and not significantly associated with time to diagnosis (P ¼ 0.12). Variables correlating with time to diagnosis included: being British (correlation coefficient þ0.268, P ¼ 0.007), Caribbean or African (-0.159, P ¼ 0.011), presenting to a specific tertiary referral centre (0.139, P ¼ 0.026), being referred by a paediatrician (-0.130, P ¼ 0.037) and having nephritis (-0.138, P ¼ 0.027), immunological disorder (-0.125, P ¼ 0.046) or haematological disorder (-0.164, P ¼ 0.09) at presentation. A linear regression model identified being of Caribbean/African (P ¼ 0.006) or Asian (P ¼ 0.045) ethnicity, being referred by a paediatrician (P ¼ 0.047) or having nephritis (P ¼ 0.045) at presentation as independent predictors of shorter time to diagnosis. Conclusion: Within this cohort, ethnic origin and the initial source of referral were strong predictors of interval in establishing diagnosis of JSLE. LN at presentation is a significant independent predictor of shorter time to diagnosis. Gender, age at presentation, ACR score, distance from nearest tertiary paediatric rheumatology service, socioeconomic status and family history of autoimmune disease were not found to be significant predictors of access to care. Disclosure statement: The authors have declared no conflict of interest. (5.4) . Median ages at diagnosis within this group were 8.2 years for females (IQR 6.5-9.0) and 5.2 years for males (IQR 3.8-7.7). Males were significantly younger at diagnosis than females (P ¼ 0.03). The median disease duration was 4 years (IQR 1.7-7.0 years). There was a trend towards discoid rashes occurring more frequently in males, though not reaching statistical significance (male 33%, female 9%; P ¼ 0.06). There was no difference in the preponderance of arthritis in males (67%) vs females (57%) in those aged <10 years. There were no observed differences between the sexes in any of the 10 other ACR criteria either at diagnosis or latest follow-up. 9 /l, 6-147) and 6 (6%) at T12 (94 x 10 9 /l, 31-142). Two patients were thrombocytopenic at both T0 and T12. Five patients at T0 and one at T12 had platelets <50,000/mm3. Conclusions: 17% of JSLE patients in this cohort had TCP at T0, though most resolved by T12. Thrombocytopenic patients at T0 had lower C3 levels and significantly higher disease activity scores at both diagnosis and follow-up, but had not accrued more disease-related damage to date. Ongoing follow-up is taking place. Disclosure statement: The authors have declared no conflict of interest. Results: Only IgG anti-FXa antibodies were found more frequently in adult patients with SLE (n ¼ 52/106, 49.1%) compared with JSLE (n ¼ 5/33, 15.2%, P ¼ 0.001). There was no statistically significant difference in anti-FVIIa or anti-Thr between these two groups. In contrast, only anti-Thr levels were elevated (n ¼ 17/35, 48.6%) in patients with JSLE compared with JIA (n ¼ 1/14, 7.1%, P < 0.01) and there was no difference between anti-FXa and anti-FVIIa levels, which were low for both groups. Conclusion: Of the anti-SP antibodies tested, levels of anti-FXa antibodies were useful in distinguishing between patients with adult and juvenile onset SLE whilst levels of anti-Thr antibodies distinguished JSLE from JIA controls but not from adult onset SLE. Further studies are now underway to correlate these findings with the clinical and serological phenotype of juvenile and adult onset disease. Results: Eight citations found, four cross-sectional studies, three cohort studies and one review. Conclusion: Vitamin D deficiency in juvenile systemic lupus erythematosus is associated with low bone mineral density. Studies suggest that reduced bone mineral density is related to cumulative steroid dosage, and levels of vitamin D are associated with increased disease duration and severity in JSLE. Vitamin D deficiency is commonly found at diagnosis and may need higher than standard dosage supplementation. Further research is required for optimal level of supplementation in varying disease status. Background: JDM is a rare autoimmune vasculopathy affecting primarily the muscle and skin. Early and aggressive treatment improves outcome and prevents complications. Cyclophosphamide has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the effectiveness of cyclophosphamide in JDM is limited to small case series and case reports. Objective: To describe the response to cyclophosphamide in patients with severe or refractory JDM. Methods: 56 patients treated with cyclophosphamide between 2000 and 2011 were identified in the JDM National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. 8 patients were excluded due to incomplete data or too short follow-up. For the 48 patients included, demographics, myositis core outcome variables, skin measures, laboratory measures, steroid dose and other treatments were recorded at baseline, and at 6-, 12-, 18-, 24-month and last follow-up after commencement of the drug. Results: Indications for starting cyclophosphamide were ulcerative or severe skin disease, profound muscle weakness, lung disease, gastrointestinal vasculopathy or refractory disease. All patients starting with muscle weakness (n ¼ 44) significantly improved at 12 months, and the gains were maintained at follow-up. Physician VAS was available for 32 patients and these all improved by 12 and 24 months, and for 31 remained stable at follow-up. At the last follow-up 26/46 (56%) had no rash, 32/46 (69%) had normal nailfolds, 37/45 (82%) had no Gottron's and calcinosis improved in 9/14 (64%). Conclusions: This study, the largest to date, demonstrated significant improvement in both muscle and skin domains in patients with JDM treated with i.v. cyclophosphamide. Cyclophosphamide appears to be effective in the treatment of severe or refractory JDM. Disclosure statement: The authors have declared no conflict of interest. Bristol Royal Hospital for Children, Bristol, UK Correspondence to: nr8035@bris.ac.uk Background: Chronic recurrent multifocal osteomyelitis (CRMO) is an inflammatory bone disease occurring primarily in children and adolescents. Currently, due to the lack of awareness of the disease and the absence of specific diagnostic tests, children undergo many investigations and treatments before a diagnosis is finally reached. In our description of the findings from a large cohort of children with CRMO we outline common features enabling earlier recognition and diagnosis. Objective: The aim of the study was to describe the clinical and radiological features, the response to different therapies and the outcomes in a cohort of patients with CRMO. This was done by completing a retrospective case-note and imaging review of children undergoing assessment and treatment at Bristol Children's Hospital.
SAFETY AND EFFICACY OF US-GUIDED HIP INJECTIONS
PREDICTORS OF ACCESS TO CARE IN JSLE: EVIDENCE FROM THE UK JSLE COHORT STUDY
GENDER DIFFERENCES IN THE ACR CLASSIFICATION CRITERIA IN PATIENTS DIAGNOSED WITH JUVENILE ONSET SLE YOUNGER THAN 10 YEARS
PROFILING ANTIBODIES TO SERUM PROTEASES IN PATIENTS WITH JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS
CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS: A CASE SERIES ANALYSIS
Methods: Case-notes of 38 patients undergoing treatment for CRMO from 2003 to 2012 at Bristol Children's Hospital were analysed and details entered into a custom-made spreadsheet containing 82 parameters. In order to establish the criteria that had been used for diagnosis, plain films, CT, MRI, bone scans and biopsy results were recorded. Results: The most common presenting location of bony swelling was the clavicle (29%), followed by tibia (26%), femur (24%) and spine (21%). The preceding differential diagnoses considered were infectious osteomyelitis (26%), Langerhans cell histiocytosis (13%) and malignancy (11%). The median age of the cohort is 9 years (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , with a female:male ratio of 29:9. All children had plain radiographs, many of them substantial in number. Fifty-three per cent of children received prolonged courses of antibiotics prior to diagnosis. MRI STIR was performed in 71% of patients, all showing characteristic signal enhancement. Biopsies were taken in 71% of cases and bone scans in 42%. Thirty-three (87%) were treated with NSAIDs with 16 (48%) suffering from breakthrough pain. These 16 patients were treated with bisphosphonate therapy. Other treatments included DMARDs (21%) and steroids (13%). These results were similar to those found in published reviews. Conclusion: This cohort is one of the largest series in the literature. It is important to increase awareness of CRMO as a diagnostic differential when a child presents with insidious onset bone pain. MRI STIR provides important evidence in the diagnosis of CRMO and may prevent the use of unnecessary radiation and treatment by aiding earlier diagnosis. A central database would facilitate a greater understanding of the diagnostic criteria and treatment options. Disclosure statement: The authors have declared no conflict of interest. Background: The presentation of a single swollen knee joint in a child can pose a diagnostic dilemma that requires a timely and correct diagnosis to avoid complications and unnecessary investigations. This study concentrates on two of these differentials; septic arthritis (SA), which needs emergency management, and JIA, where aggressive management such as synovial biopsy can be avoided. The aim is to identify clinical findings and routine laboratory investigations that could aid in the early and appropriate diagnosis, with referral to the correct specialist. Methods and materials: A retrospective review was performed using the case-notes of 44 children presenting with a single swollen knee joint between 2000 and 2010 with a definitive diagnosis of either SA or JIA. Comparisons of features potentially predicative of the final diagnosis were compared using univariate analysis and multivariate analysis. Results: Three of the five factors identified as significantly suggesting SA over JIA are identified via history and examination; these are fever, being unwell and duration of onset. Three routinely investigated factors, WBC, CRP and ESR, were also identified as significantly different though logistic regression. Two sample t-test and Fisher's exact test also identified a raised neutrophil count, non-weight bearing, lack of signs of chronic joint damage and a hot joint as important factors. Stepwise regression found a combination of CRP >7 nmol/l, onset <4 days and the child being generally unwell as significantly indicative of SA. Conclusion: Routinely performed investigations and a detailed history of onset are useful in differentiating between SA and JIA. Identification of these features will potentially allow for a more timely and accurate diagnosis of a single swollen knee. Background: Mucopolysaccharidoses (MPSs) are rare inherited disorders with a spectrum of phenotypes resulting from glycosaminoglycans (GAGs) accumulating in cells. Children with MPS often have musculoskeletal (MSK) abnormalities ranging from joint contractures to deforming abnormalities of the extremities and spine. Paediatric gait, arms, legs, and spine (pGALS), is a simple MSK assessment and previously validated in school-age children to detect abnormal joints. Objective: Our aim was to describe the use of pGALS to identify patterns of MSK abnormalities in children with MPS. Methods: Videos of children with a spectrum of MPS performing pGALS were made at an MPS specialist centre as part of their routine care and independent of the current study. Informed consent for the use of the videos for research was obtained. A piloted proforma to record abnormalities for each pGALS manoeuvre observed in the videos (scored as normal/abnormal/not assessable) was used by three observers [two paediatric rheumatology (PRh) trainees and one specialist PRh physiotherapist and all blinded to MPS subtype]. Videos were scored independently by the three observers and videos rescored for intra-and inter-observer consistency. Data were pooled and analysed. Results: 15 videos of children [9 boys, 6 girls, median age 11 years (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) Background: Referral letters (RLs) to Paediatric Rheumatology (PR) often lack key information to facilitate correct triage. Strategies to enhance the quality of referrals include providing referral guidelines and targeted PR teaching. Objective: The aim of this study was to assess the quality of RL sent from the Accident and Emergency (AþE) department to PR, and any change in quality after PR teaching. Methods: An audit was conducted of the quality of AþE RL to PR written between 2007 and 2012. The quality of RL was graded and comparison of RL written before or after targeted PR teaching was made. Information from the Canadian Rheumatology Association was used to identify the requirements of a RL to rheumatology. Each RL was assigned a grade from 0 (weakest) to 3 (excellent). Results: 74 RLs were reviewed from AþE staff (24 consultants, 38 AþE trainees, 7 GP trainees and 5 paediatric trainees). Only 20 RL included a diagnosis that matched the PR diagnosis. 34 RLs contained no differential diagnosis. The most common PR diagnoses in this study were JIA (15) and reactive arthritis (15) and these diagnoses were made in 12 of 30 RLs. The most common presenting complaint was limp (17 RLs) of which only 6 RLs made a diagnosis that matched the final PR diagnosis. Hip pain was the worst matched symptom for accurate diagnosis (0/12 RLs). 22 out of 74 patients were discharged at their first PR appointment without needing any intervention other than providing a diagnosis [reactive arthritis (8), normal or resolved (6), benign hypermobility (3), transient synovitis of hip (1)]. 38 RLs were recorded as either grade 2 or 3, with the AþE trainees sending the most grade 3 letters (5/11). The number of high-quality RLs was unchanged after teaching. The number of grade 0 letters fell from 9 to 3 after teaching. Conclusion: The overall quality of RLs was better than previously published. A pre-referral checklist could prove beneficial. PR teaching improves doctors' understanding of paediatric musculoskeletal disorders but could be targeted to improve confidence in managing benign conditions, avoiding unnecessary referral, and confidence in diagnosing hip presentations and JIA. Disclosure statement: The authors have declared no conflict of interest. Background: Levamisole is an antihelminthic agent with immunomodulating properties that is used to reduce the risk of relapse in children with frequently relapsing steroid-dependent nephrotic syndrome. It has been reported to be associated with circulating autoantibody formation and vasculitis in both adults and children [1] [2] [3] . Case report: We report the case of an 8-year-old girl who developed ANCA-positive vasculitis following a prolonged course of levamisole. She was diagnosed with steroid-dependent nephrotic syndrome aged 4 and commenced on levamisole in addition to low dose alternate day prednisolone the following year due to frequent relapses. She had been taking levamisole for 42 months when she presented with fever, lethargy, polyarticular arthritis and a blanching erythematous rash. Abdominal US revealed splenomegaly, ESR and CRP were raised and blood film was normal. P-ANCA was strongly positive with both MPO and PR3 antibodies detected. She was treated initially with ibuprofen and cessation of levamisole. Six weeks after stopping levamisole she was readmitted with ongoing arthritis, lethargy, splenomegaly and a vasculitic rash on both thenar eminences. ESR and CRP remained high. She was treated with four doses of i.v. methylprednisolone and a weaning course of oral prednisolone over 6 weeks. Her symptoms resolved and inflammatory markers normalized with this treatment but ANCA positivity persisted at follow-up 2 months later with negative PR3 and a reduced titre of MPO. In summary we report a case of levamisole-associated ANCA-positive vasculitis that occurred after 42 months of drug exposure and responded promptly to treatment with i.v. methylprednisolone. This is in contrast to previous paediatric reports in which symptoms resolved following withdrawal of levamisole and specific treatment was not required [1] [2] [3] . It is important for both paediatric rheumatologists and nephrologists to be aware of this significant potential adverse effect of levamisole, which tends to present following prolonged exposure and may require treatment for persisting symptoms despite withdrawal of the drug. Case report: We present the case of an 8-year-old girl who initially presented with pyrexia, lethargy, anorexia, weight loss, arthralgia and a dry cough. She had a vasculitic rash on her palms and feet, lymphopenia and raised amylase. A skin biopsy revealed IgA deposits. She also developed acute tubular necrosis. Her working diagnosis at this stage was systemic vasculitis of undetermined cause and she was treated with i.v. methylprednisolone and plasma exchange with good response. She re-presented a month later with acute encephalopathy. She developed secondary haemophagocytic lymphohistiocytosis and was treated with dexamethasone, IVIG and ciclosporin. An MRI brain revealed a brain stem infarct and she developed cardiac dysfunction. She required intubation and ventilation and was also treated with cyclophosphamide, plasma exchange, antihypertensives and inotropes. She was commenced on pulsed i.v. cyclophosphamide following discharge. Initially her autoantibodies were all negative, however, almost a year after her initial presentation her antimitochondrial antibodies became positive at 1:80, shortly followed by a positive ANA of 1:100 and positive anti-dsDNA antibodies of 18. She was admitted with an episode of neutropenic sepsis at this time and responded well to i.v. antibiotics. A diagnosis of SLE was assigned and it was planned to commence her on rituximab, however, on routine blood testing she was found to have deranged liver function. She was admitted for monitoring and rapidly deteriorated with acute pancreatitis, bradycardia and fluctuating levels of consciousness. She was commenced on plasma exchange and received rituximab. Due to her immunosuppression she was on broad-spectrum antibiotics and antifungal agents. Unfortunately she developed multi-organ failure and overwhelming sepsis, growing invasive Enterococcus faecium in her blood cultures as well as Candida in her urine, Pseudomonas in her sputum, Aspergillus in her pleural fluid and cytomegalovirus in her blood. She required intubation and ventilation, high-dose inotropic support and haemodiafiltration. Two weeks after her admission she deteriorated further and her blood pressure became increasingly labile. A CT brain showed multiple infarcts and communicating hydrocephalus. Her brain began to cone and despite maximum supportive therapy she was pronounced brainstem dead. Support was withdrawn at this stage and she passed away several hours later. This case demonstrates both the variability in the presentation of SLE and the devastating consequences the disease can have. Introduction: The art of history taking is most challenging to the paediatrician. The basic human responses we rely on as physicians are usually inhibited, distorted or exaggerated. A delay in the correct diagnosis can lead to further complications, as seen with numerous childhood diseases. This case highlights some of the essential learning points to consider when approaching the unwell child with seemingly normal clinical parameters. Background: A 4-year-old girl presented with non-specific abdominal pain and a raised temperature. Studies have shown that fewer than 1 in 10 children febrile on admission have an underlying significant bacterial infection. Surgical review and investigations ruled out the diagnosis of appendicitis and she was discharged later that day. Fortyeight hours later the patient was readmitted after blood cultures taken on the previous admission grew Staphylococcus aureus. A rise in inflammatory markers indicated an MRI scan of the hips, revealing a focal 2 cm abscess formation in the left adductor brevis muscle, with similar changes on the right. The paediatric orthopaedic team deemed drainage of the collection unnecessary. Clinical improvement followed a 2-week course of i.v. flucloxacillin and the patient was discharged with a 16-day course of oral flucloxacillin. A review of the case illustrated a possible cause, a history of impetigo followed by prolonged exposure to horse riding. Discussion: The repeated activity of horse riding has been shown to apply strain to the adductor brevis muscle, which may have caused an injury and contributed towards the abscess formation.
PAMIDRONATE THERAPY FOR CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS: A CASE SERIES ANALYSIS
ANCA-POSITIVE VASCULITIS ASSOCIATED WITH LEVAMISOLE
Conclusion:
In an age where high-resolution imaging and advanced laboratory techniques are changing the way in which we diagnose patients, the fundamental principles of clinical practice must not be forgotten. We still possess the most powerful weapon in combating illness, a thorough and targeted history followed by a detailed and relevant examination. Disclosure statement: The authors have declared no conflict of interest.
